EXG PulseLinQ Cables (EXGPL)
Cb Innovations, LLC · Decision date Oct 30, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 10/30/2026 for EXG PulseLinQ Cables (EXGPL), submitted by Cb Innovations, LLC of Carlsbad, California, under 510(k) number K262816. The application was received 08/07/2026 as a Traditional 510(k) and was not reviewed by a third party. The device falls under product code DSA, regulation 870.2900, for cable, transducer and electrode, patient (including connector), with a Cardiovascular regulation medical specialty and Cardiovascular review panel.
SESE in this 510(k) context means the submitted device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The record lists no combination product and no authorized predetermined change control plan. The available source does not identify the predicate device, describe the specific components or changes submitted, or give indications for use; those details would sit in the linked summary document, which was not reviewed here.
No clinical, efficacy or patient-selection conclusions are drawn from this clearance record.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262816
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Cb Innovations, LLC
- Product code
- DSA
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cable, Transducer And Electrode, Patient, (Including Connector).
- Applicant
- Cb Innovations, LLC
- Product code
- DSA
- FDA device class
- 2
FDA decision timeline
K262816 received
Application receipt date recorded by FDA.
K262816 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cb Innovations, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Carlsbad, CA
Sources and methodology
- Original FDA record: K262816
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records